Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide vs PCV in Recurrent High-Grade Glioma
NCT00052455Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioma (3 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Overall Survival. Started Oct 2002; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00052455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052455.